| Karen Lee Mccurnin, CRNA | |
|
2700 Hospital Dr, Northport, AL 35476-3360 | |
| (205) 759-7352 | |
| (205) 759-6397 |
| Full Name | Karen Lee Mccurnin |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 22 Years |
| Location | 2700 Hospital Dr, Northport, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912940842 | NPI | - | NPPES |
| 054982 | Other | AL | AMERICAN ASSOCIATION OF NURSE ANESTHETISTS (CERTIFICATION) |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 1-062841 (Alabama) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 1-062841 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| D C H Regional Medical Center | Tuscaloosa, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northport - Crna | 3971791286 | 18 |
News Archive
A study with first-time learners of Japanese has measured how brain activity changes after just a few months of studying a new language. The results show that acquiring a new language initially boosts brain activity, which then reduces as language skills improve.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.
› Verified 8 days ago
| Entity Name | Northport - Crna |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265734271 PECOS PAC ID: 3971791286 Enrollment ID: O20101230000056 |
News Archive
A study with first-time learners of Japanese has measured how brain activity changes after just a few months of studying a new language. The results show that acquiring a new language initially boosts brain activity, which then reduces as language skills improve.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen Lee Mccurnin, CRNA 809 University Blvd E, Tuscaloosa, AL 35401-2029 Ph: (205) 759-7352 | Karen Lee Mccurnin, CRNA 2700 Hospital Dr, Northport, AL 35476-3360 Ph: (205) 759-7352 |
News Archive
A study with first-time learners of Japanese has measured how brain activity changes after just a few months of studying a new language. The results show that acquiring a new language initially boosts brain activity, which then reduces as language skills improve.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.
› Verified 8 days ago
Robert T Rumanek, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2700 Hospital Dr, Northport, AL 35476 Phone: 205-333-4500 Fax: 205-333-4916 | |
Mr. Newton Hinton Tinsley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2700 Hospital Dr, Northport, AL 35476 Phone: 205-799-4907 | |
Shannon L Montgomery, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2700 Hospital Dr, Northport, AL 35476 Phone: 205-333-4500 | |
William Gordon Walker, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2700 Hospital Dr, Northport, AL 35476 Phone: 205-759-7352 Fax: 205-759-6397 |